首页> 外文期刊>Arthritis Research >Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
【24h】

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials

机译:基于高分辨率计算机体层摄影术的硬皮病相关性间质性肺病肺功能下降的预测指标:对系统性硬化症相关性间质性肺病试验中人群富集的影响

获取原文
       

摘要

Background The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the Scleroderma Lung Study I (SLS I) over a 1-year period. Methods We assessed two visual semiquantitative scores: the maximum fibrosis score (MaxFib, the fibrosis score in the zone of maximal lung involvement) and visual assessment of total lung involvement (TLI) as proposed by Goh and Wells. In addition, we evaluated the computer-aided diagnosis and calculated the quantitative percentage with fibrosis (QLF) and TLI. Results The mean duration of the disease was 3.2?years, and the mean FVC was 67.7?%. Regardless of the staging system used, a greater degree of fibrosis/TLI on HRCT scans was associated with a greater decline in FVC in the placebo group. Using the MaxFib and QLF, the mean absolute changes in FVC from baseline were 0.1?% and ?1.4?%, respectively, in 25?% involvement (negative score denotes worsening in FVC). Conversely, cyclophosphamide was able to stabilize decline in FVC in subjects with greater degree of involvement detected by HRCT. Using the visual MaxFib and QLF, the mean absolute improvements in FVC were 1.2 and 1.1, respectively, with >25?% involvement. Conclusions HRCT-defined lung involvement was a predictor of decline in FVC in SLS I. The choice of staging system for cohort enrichment in a clinical trial depends on feasibility. Trial registration ClinicalTrials.gov identifier: {"type":"clinical-trial","attrs":{"text":"NCT00004563","term_id":"NCT00004563"}} NCT00004563 (Scleroderma Lung Study I) ISRCTN15982171. Registered 19 Aug 2015. Electronic supplementary material The online version of this article (doi:10.1186/s13075-015-0872-2) contains supplementary material, which is available to authorized users.
机译:背景技术高分辨率计算机断层扫描(HRCT)可视化的肺部受累程度是硬皮病-间质性肺病中强迫肺活量(FVC)下降的预测指标。我们的目标是评估硬皮病肺研究I(SLS I)在1年期间的三种不同HRCT定义的分期系统的性能。方法我们评估了两个视觉半定量评分:最大纤维化评分(MaxFib,最大肺部受累区域的纤维化评分)和Goh和Wells提出的视觉评估总肺部受累(TLI)。此外,我们评估了计算机辅助诊断并计算了纤维化(QLF)和TLI的定量百分比。结果该病平均病程为3。2年,平均FVC为67.7%。不管使用何种分期系统,在HRCT扫描中纤维化程度/ TLI程度越高,安慰剂组FVC下降幅度越大。使用MaxFib和QLF,参与度为25%时,FVC与基线相比的平均绝对变化分别为0.1%和1.4 %%(负评分表示FVC恶化)。相反,在HRCT检测到受累程度较高的受试者中,环磷酰胺能够稳定FVC的下降。使用视觉MaxFib和QLF,FVC的平均绝对改善分别为1.2和1.1,参与度> 25%。结论HRCT定义的肺部受累是SLS I FVC下降的预测指标。在临床试验中选择用于人群富集的分期系统取决于可行性。试验注册ClinicalTrials.gov标识符:{“ type”:“ clinical-trial”,“ attrs”:{“ text”:“ NCT00004563”,“ term_id”:“ NCT00004563”}} NCT00004563(肺硬皮病研究I)ISRCTN15982171。 2015年8月19日注册。电子补充材料本文的在线版本(doi:10.1186 / s13075-015-0872-2)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号